VRCA: Verrica Pharmaceuticals Inc. 2020-11-10 07:30:00 Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)
VRCA Breaks below 30 RSI and has rebounded every time. Momentum is building, get ride it to $12 - $15.
Once RSI dips below 30 again opening position then dumping at 12.21.
VRCA has been tanking the last few days due to FDA Approval Delays Has a history of bouncing around support and resistance levels around this price Upside is around 80% if positive PR and price action takes place with the weeks Low Float stock, can be volatile. (Enjoy the ride)